|
2,121
|
| 17385 |
AD11 anti-NGF mouse
|
|
affects_activity of
|
complement activation
|
|
|
19604602
|
Alzheimer disease
|
|
4,119
|
| 42784 |
Myelin-antibody
|
|
increases_activity of
|
complement activation
|
|
| 42785 |
complement activation
|
|
increases_activity of
|
opsonization
|
of myelin and oligodendrocytes
|
| 42786 |
complement activation
|
|
increases_activity of
|
phagocytosis
|
of myelin and oligodendrocytes
|
|
23482896
|
Multiple sclerosis
Glaucoma
Infantile spasm
|
|
6,911
|
| 67589 |
CFB
|
|
affects_activity of
|
complement activation
|
|
|
24739633
|
Inflammatory bowel disease 1
Immunological
Inflammatory bowel disease
|
|
6,928
|
| 67764 |
SERPING1
|
|
decreases_activity of
|
complement activation
|
|
|
20338925
|
Inflammatory bowel disease 1
Inflammatory bowel disease
|
|
6,945
|
| 67870 |
C3
|
|
affects_activity of
|
complement activation
|
|
|
20089077
|
Inflammatory bowel disease
|
|
7,879
|
| 78401 |
complement activation
|
|
increases_activity of
|
atherosclerotic lesions
|
|
| 78543 |
OxLDL
|
|
increases_activity of
|
complement activation
|
|
| 78544 |
complement activation
|
|
increases_quantity of
|
Terminal complement C5b-9 complex
|
|
| 78549 |
complement activation, classical pathway
|
|
increases_activity of
|
complement activation
|
|
| 78550 |
complement activation, alternative pathway
|
|
increases_activity of
|
complement activation
|
|
| 78551 |
complement activation, lectin pathway
|
|
increases_activity of
|
complement activation
|
|
| 78552 |
complement activation
|
|
increases_activity of
|
C3
|
|
|
26091721
|
Immunological
Atherosclerosis
|
|
7,880
|
| 78402 |
complement activation
|
|
increases_activity of
|
Insulin resistance
|
in subcutaneous adipose tissue
|
|
23055543
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,900
|
| 78441 |
complement activation, classical pathway
|
|
increases_activity of
|
complement activation
|
|
| 78718 |
complement activation, lectin pathway
|
|
increases_activity of
|
complement activation
|
|
| 78719 |
complement activation, alternative pathway
|
|
increases_activity of
|
complement activation
|
|
| 78725 |
complement activation
|
|
decreases_quantity of
|
C3
|
|
| 78726 |
complement activation
|
|
increases_quantity of
|
C3a
|
|
| 78727 |
complement activation
|
|
increases_quantity of
|
C3b
|
|
| 78777 |
cholesterol crystal
|
|
increases_activity of
|
complement activation
|
|
|
27692470
|
Immunological
Atherosclerosis
|
|
8,030
|
| 79375 |
CFH
|
|
increases_activity of
|
complement activation
|
|
|
19076828
|
Immunological
Atherosclerosis
|
|
12,080
|
| 118720 |
SARS infection
|
|
affects_activity of
|
complement activation
|
|
| 118721 |
complement activation
|
|
increases_quantity of
|
C3a
|
|
| 118722 |
complement activation
|
|
increases_quantity of
|
C5a
|
|
| 118723 |
complement activation
|
|
increases_activity of
|
inflammatory response
|
|
| 118724 |
complement activation
|
|
increases_activity of
|
thrombosis
|
|
| 118725 |
complement activation
|
|
increases_quantity of
|
VWF
|
|
| 118726 |
complement activation
|
|
increases_quantity of
|
MASP1
|
|
| 118727 |
complement activation
|
|
increases_quantity of
|
MASP2
|
|
|
32348783
|
Cardiovascular disease
COVID-19
|
|
12,083
|
| 118732 |
Thrombin
|
|
increases_activity of
|
complement activation
|
|
| 126586 |
MASP1
|
|
increases_activity of
|
complement activation
|
by activation of prothrombin to thrombin leading to proteolytic cleavage of fibrinogen to fibrin
|
|
32348783
|
Cardiovascular disease
COVID-19
|
|
12,114
|
| 118923 |
complement activation, classical pathway
|
|
increases_activity of
|
complement activation
|
|
| 118924 |
complement activation, lectin pathway
|
|
increases_activity of
|
complement activation
|
|
| 118925 |
complement activation, alternative pathway
|
|
increases_activity of
|
complement activation
|
|
| 118931 |
complement activation
|
|
increases_quantity of
|
C4d
|
|
|
19362461
|
Cardiovascular disease
|
|
12,178
|
| 119289 |
COVID-19
|
|
increases_activity of
|
complement activation
|
|
| 119364 |
complement activation
|
|
affects_activity of
|
innate immune response
|
|
| 119365 |
complement activation
|
|
affects_activity of
|
defense response to virus
|
|
| 119367 |
complement activation
|
|
increases_activity of
|
C5a
|
|
| 119388 |
complement activation
|
|
affects_quantity of
|
C3
|
|
| 119389 |
complement activation
|
|
affects_quantity of
|
C3a
|
|
| 119390 |
complement activation
|
|
affects_quantity of
|
Terminal complement C5b-9 complex
|
|
| 119391 |
complement activation
|
|
affects_quantity of
|
C5a
|
|
|
32544563
|
COVID-19
|
|
13,173
|
| 124974 |
APOE (isoform E4)
|
|
affects_activity of
|
complement activation
|
in APOE4 carriers with AD, with aggregated amyloid beta, with normal cognition ; via altered concentrations of proteins involved in the complement pathway
|
| 124993 |
Alzheimer disease
|
|
affects_activity of
|
complement activation
|
in APOE4 carriers with AD, with aggregated amyloid beta, with normal cognition ; via altered concentrations of proteins involved in the complement pathway
|
|
32460813
|
Alzheimer disease
|
|
13,275
|
| 125645 |
Nephropathy, diabetic
|
|
affects_activity of
|
complement activation
|
|
|
31942046
|
Nephropathy, diabetic
|
|
13,371
|
| 126036 |
C5A
|
|
affects_activity of
|
complement activation
|
|
|
19464229
|
Hematological
|
|
13,513
|
| 127437 |
C1QBP
|
|
increases_activity of
|
complement activation
|
|
|
11859136
|
Immunological
Inflammation
|
|
13,518
|
| 127455 |
innate immune response
|
|
increases_activity of
|
complement activation
|
|
|
16177118
|
Immunological
|
|
13,621
|
| 128183 |
Nephropathy, diabetic
|
|
increases_activity of
|
complement activation
|
|
| 128185 |
complement activation
|
|
affects_activity of
|
proton-transporting ATP synthase complex
|
|
| 128186 |
complement activation
|
|
affects_quantity of
|
Reactive oxygen species
|
|
| 128188 |
complement activation
|
|
affects_expression of
|
SOD2
|
in glomeruli
|
|
32161193
|
Immunological
Nephropathy, diabetic
|
|
14,093
|
| 133242 |
COVID-19
|
|
increases_activity of
|
complement activation
|
|
|
32651579
|
COVID-19
|
|
15,273
|
| 144429 |
complement activation
|
|
increases_quantity of
|
C3a
|
|
| 144431 |
complement activation
|
|
increases_quantity of
|
C5a
|
|
| 144453 |
Amyloid beta peptide
|
|
increases_activity of
|
complement activation
|
in AD; by binding to C1q
|
| 144456 |
complement component C1q binding
|
|
increases_activity of
|
complement activation
|
in AD; via binding of Abeta
|
|
|
Alzheimer disease
|
|
15,306
|
| 144724 |
SERPING1
|
|
affects_activity of
|
complement activation
|
in hippocamus and mPFC.
|
|
|
Schizophrenia
|
|
15,425
|
| 145886 |
metabolic acidosis
|
|
increases_activity of
|
complement activation
|
|
|
|
Renal
Chronic kidney disease
|
|
15,745
|
| 149564 |
TGFB1
|
|
increases_activity of
|
complement activation
|
in neurons; concerning astrocyte-derived TGF-beta,
acting on microglia
|
| 149565 |
complement activation
|
|
affects_activity of
|
microglia
|
in neurons; via astrocyte-derived TGF-beta
|
|
|
Alzheimer disease
|
CIDeRplus